Progression of Hematopoietic Diseases in Shanghai, China

July 19, 2013 updated by: University of Colorado, Denver

Analysis of Disease Progression for Aplastic Anemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia and Benzene Poisoning in Shanghai, China.

The purpose of this study is to identify and characterize blood diseases presenting at Shanghai hospitals and to compare them with respect to clinical presentation, phenotype, molecular characteristics, benzene or other exposures and genetic susceptibility.

Study Overview

Status

Completed

Conditions

Detailed Description

The purpose of this study is to identify and characterize blood diseases presenting at Shanghai hospitals and to compare them with respect to clinical presentation, phenotype, molecular characteristics, benzene or other exposures and genetic susceptibility. The format for these studies is a set of clinical series superimposed on a case-control design that enables integration of detailed clinical and molecular characterizations of disease pathogenesis together with an evaluation of potential confounding and interacting factors within a structured statistical analysis of benzene exposure.

Study Type

Observational

Enrollment (Actual)

10757

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
      • Shanghai, China, 200032
        • Joint Sino-US Clinical and Molecular Laboratory (JCML)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with blood diseases

Description

Inclusion Criteria:

Men and women 18 years or older Diagnosis of hematologic abnormality

Exclusion Criteria:

Children Non hematologic diseases

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Blood disease patients
People with blood diseases presenting at Shanghai hospitals

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
blood diseases presenting at Shanghai hospitals
Time Frame: hospital stay
characterization of people with blood diseases presenting at Shanghai hospitals
hospital stay

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Colorado, Denver

Collaborators

Fudan University
University of Cincinnati
ExxonMobil Biomedical Sciences, Inc.
British Petroleum P.L.C.
Chevron Corporation
ConocoPhillips
Exxon Mobil
Marathon Ashland
Shell Chemicals

Investigators

  • Principal Investigator: Richard D Irons, PhD, University of Colorado at Denver and Health Sciences Ctr.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2003

Primary Completion (Actual)

December 1, 2009

Study Completion (Actual)

December 1, 2009

Study Registration Dates

First Submitted

August 14, 2006

First Submitted That Met QC Criteria

August 14, 2006

First Posted (Estimate)

August 16, 2006

Study Record Updates

Last Update Posted (Estimate)

July 23, 2013

Last Update Submitted That Met QC Criteria

July 19, 2013

Last Verified

July 1, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 02-0036

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hematologic Diseases

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe